Target
AXL
1 product, 1 indication
Indications
platinum-resistant high-grade serous ovarian cancer (1 products)
Loading...
1 drug
35 abstracts
Abstract
Clinical and molecular characterization of AXL in colorectal cancer: CALGB (Alliance)/SWOG 80405 and real-world data.Org: West Virginia University Cancer Institute, Mary Babb Randolph Cancer Center, Department of Bioengineering,
Abstract
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, The Institute of Cancer Research/The Royal Marsden Hospital, Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, Cliniques Universitaires Saint-Luc,
Abstract
Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma.Org: Winship Cancer Institute of Emory University, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA,
Abstract
Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, DFCI/PCC Fellowship Program - Attendings, Yale Cancer Center,
Abstract
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors.Org: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Carbone Cancer Center, University of Wisconsin, Madison, WI, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL,
Abstract
Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study.Org: University of Miami Hospital and Clinics, Cancer Research Services, New York Oncology Hematology, Moscow City Clinical Oncology Hospital No. 1, Alexandra General Hospital,
Abstract
Cabozantinib plus atezolizumab in patients with advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II trial (CABATEN / GETNE-T1914).Org: University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario 12 de Octubre, Imas12, UCM, Hospital Universitario La Paz, IdiPAZ, Hospital Universitario Central de Asturias, ISPA, Catalan Institute of Oncology (ICO-Badalona) Germans Trias i Pujol University Hospital,
Abstract
STELLAR-303: A randomized phase 3 study of zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer.Org: Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC,
Abstract
Enhancing the efficacy of anti-PD-L1 therapy by cabozantinib in the treatment of advanced esophageal squamous cell carcinoma (ESCC): Rationales from a preclinical study.Org: National Taiwan University Cancer Center/Hospital, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, National Taiwan University Hospital Yunlin Branch,
Abstract
Phase I clinical study of FC084CSA, a high selective AXL kinase inhibitor that ameliorates tumor microenvironment and augments the effectivity of immunotherapy.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Shanghai Pulmonary Hospital, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech,
Abstract
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.Org: Dana-Farber Cancer Institute, Gustave Roussy Cancer Center, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 de Octubre,
Abstract
Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.Org: Novartis Pharma AG, F. Hoffmann-La Roche Ltd, Exelixis, Inc., VBL Therapeutics, Dana-Farber Cancer Institute,
Abstract
STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer.Org: David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Exelixis, Inc.,
Abstract
Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).Org: Vanderbilt-Ingram Cancer Center, University of Texas MD Anderson Cancer Center, University of Pennsylvania-Abramson Cancer Center, Cleveland Clinic Taussig Cancer Instititute, Massachusetts General Hospital Cancer Center and Harvard Medical School,
Abstract
A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial.Org: Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center and Weill Cornell College of Medicine,
Abstract
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC.Org: University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, MD Anderson Cancer Center,
Abstract
CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).Org: Washington University School of Medicine in St Louis, Saint Lukes Hospital,
Abstract
Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.Org: FDA/CDER, U.S. Food and Drug Administration, US Food and Drug Administration, Oncology Center of Excellence, Office of New Drugs,
Abstract
LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.Org: Department of Hematology Oncology University of Illinois of Chicago College of Medicine, University of Ilinois Chicago, Department of Surgery University of Illinois of Chicago College of Medicine, University of Illinois Chicago, Jesse Brown VAMC,
Abstract
Neoadjuvant immunotherapy in hepatocellular carcinoma: A systematic review and meta-analysis.Org: Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT, UMass Chan Medical School, Shrewsbury, MA,
Abstract
Population pharmacokinetic and exposure-response safety analyses of mecbotamab vedotin (BA3011) in patients with advanced solid tumors.Org: BioAtla, Amador Bioscience,
Abstract
AX-0085, a novel AXL kinase inhibitor, and effects on osimertinib-resistance in non–small-cell lung cancer.Org: Axceso Biopharma Co., Ltd., College of Medicine, Hanyang University, Department of Life Science, Ewha Research Center for Systems Biology, Ewha Womans University,
Abstract
AXL pathway as a target to overcome resistance to PARP inhibitors in high-grade serous ovarian (HGSOC) and triple-negative breast cancer (TNBC) cell lines.Org: Hospital Clinico Universitario de Valencia; INCLIVA; GEICAM Spanish Breast Cancer Group, INCLIVA-Biomedical Research Institute, CIBERONC - ISCIII, Instituto de Investigación Sanitaria (INCLIVA), Translational Oncology and Pathology Group,
Abstract
Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, UT Southwestern Medical Center, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Department of Medicine, Section of Hematology/Oncology, Knapp Center for Biomedical Discovery, The University of Chicago, MSMC,
Abstract
Disparities in uptake of novel therapies for acute myeloid leukemia.Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Dana-Farber Cancer Institute,
Abstract
Nivolumab usage patterns combined with TKI for mRCC: Financial toxicity and clinical outcomes from self-paying patients in India—Is low dose an option when access is limited?Org: Christian Medical College & Hospital Vellore, Christian Medical College Vellore, Department of Uro-Oncology, Chongqing University Cancer Hospital, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
First-in-human, phase I study of KC1036, a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors.Org: Clinical Trial Center and Department of Epidemiology - IRCCS Ospedale Policlinico San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, State Key Laboratory of Biotherapy, Sichuan University,
Abstract
Phase 1b study of batiraxcept (AVB-S6-500, BT) plus gemcitabine (G) and nab-paclitaxel (NP) as first-line treatment (1L) for advanced pancreatic adenocarcinoma (PDAC).Org: Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Cleveland Clinic Taussig Cancer Instititute, Gabrail Cancer Center, Roswell Park Cancer Institute, Boca Raton Regional Hospital, Lynn Cancer Institute,
Abstract
Antitumor activity of AX-0085, a novel AXL kinase inhibitor: Analysis of apoptotic cell death in triple-negative breast cancer cells.Org: Axceso Biopharma Co., Ltd., College of Medicine, Hanyang University, Department of Life Science, Ewha Womans University, Ewha Research Center for Systems Biology, Ewha Womans University, College of Pharmacy, Seoul National University,
Abstract
Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
Correlations between overall response rate, progression-free survival and overall survival with kinase inhibitors in radioiodine-refractory differentiated thyroid cancers: A systematic review and meta-analysis.Org: One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn ImmunoTherapeutics, Nykode Therapeutics,
Abstract
KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Oncology Department, the First Affiliated Hospital of Xinxiang Medical College, Chongqing University Three Gorges Hospital & Chongqing Three Gorges Central Hospital, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Tianjin Medical University Cancer Institute & Hospital,National Clinical Research Center for Cancer,
Drug
AVB-500